Precision Neuroscience raises $250m as investors price the brain interface race

Precision Neuroscience, the New York developer of a brain-computer interface that rests on the surface of the brain rather than piercing it, said on Thursday, September 24, that it had closed an oversubscribed $250m Series D. The round was co-led by Pershing Square, the Ackman Oxman Institute and a life sciences investment fund that the company did not name. According to The New York Times, as reported by The Next Web, the financing values the company at just over $1bn, and Pershing Square and the institute together put in $42.5m of the total.

The round brings the company's total funding to $430m since it was founded in 2021, up from about $180m before this round. It also roughly doubles the price set in December 2024, when Precision raised a $102m Series C at a post-money valuation of about $500m. For a company whose only cleared product is a temporary implant, that is a large vote of confidence, and it says as much about how investors now view the brain-computer interface sector as a whole as it does about Precision itself.

Who wrote the cheques

The list of backers is unusually broad for a medical device company at this stage. Alongside the three co-leads, the round included Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital. That mix of a hedge fund manager's family of vehicles, a sovereign-linked investor, Korean institutions, a corporate venture arm and a thematic public markets house is closer to the shape of a late-stage technology round than a traditional medtech syndicate.

The Ackman Oxman Institute, a Manhattan brain research centre that Bill Ackman co-founded with his wife, Neri Oxman, is making its first investment, according to the Times. Mr Ackman said Precision's less invasive approach was what drew him in, adding that "the brain can recover from even catastrophic injury". ARK Invest's presence is also notable because it is an investor in Neuralink, Precision's best-known rival. Thematic investors are evidently treating the category as one in which it pays to hold more than one ticket.

A less invasive bet

Precision's core product, the Layer 7 Cortical Interface, is a thin-film array of 1,024 electrodes that rests on the brain's surface. In April 2025 it received FDA 510(k) clearance to record, monitor and stimulate electrical activity on the surface of the brain for implantation periods of up to 30 days, where earlier use had been limited to the hours of a single procedure. The company described that decision as the first full regulatory clearance for a company developing a next-generation wireless brain-computer interface. The clearance covers the array only: the complete wireless system of which it is a part is still in development.

The design choice is the heart of the investment case. Neuralink threads electrodes into brain tissue using its own surgical robot. Synchron, which counts Jeff Bezos among its backers, reaches the brain through blood vessels. Precision sits between the two: its array lies on the cortex without penetrating it. One of Precision's co-founders, Benjamin Rapoport, was also a co-founder of Neuralink, which gives the company's view of the trade-offs a certain credibility.

Clinical experience has grown quickly. At the time of the clearance in April 2025, the company reported testing in 37 patients through partnerships with Mount Sinai Health System, the Perelman School of Medicine at the University of Pennsylvania, West Virginia University's Rockefeller Neuroscience Institute and Beth Israel Deaconess Medical Center. It now says it has performed more than 100 procedures at 18 medical centres. In January it agreed a partnership with Medtronic to integrate its electrode array with surgical navigation systems.

What the money is for

According to the Times, the Series D will support the company's pursuit of approval for permanent implants. The more important ambition is a fully implantable, wireless system, of which today's array is only one component. The company is preparing an early feasibility study of such a system for people with severe paralysis. Chief executive Michael Mager told the Times that winning approval for permanent implants is likely to take years.

That timeline is the crux for investors. A 30-day clearance allows the company to gather data and build relationships with neurosurgeons, but it is not the product that would justify a $1bn valuation on its own. The value lies in a permanent device used by large numbers of patients and paid for by insurers, and none of that is yet in place. Mr Mager's own framing, that the next phase of the field will be defined by more than technology alone, points to the real work ahead: clinical evidence, regulatory standing, manufacturing at scale and reimbursement.

A crowded and expensive field

Precision is raising in a market that has suddenly become generous. Neurofounders, cited by The Next Web, estimates that more than $2bn has flowed into brain-computer interface companies in the past 18 months. Paradromics placed its first brain chip in a patient in June, and China implanted its first commercial brain implant in a patient in July.

Plenty of capital and several credible approaches mean that no single company can assume it will set the standard. Device markets tend to reward the first company to secure a permanent approval and a reimbursement code, then the one with the best surgical workflow. Precision's partnership with Medtronic is an attempt to win on the second front even if it does not win the first.

Our view

This is a well-constructed round for a company that has done the unglamorous work: a cleared device, a real clinical network and a partnership with Medtronic. A valuation of roughly $1bn is not extravagant by the standards of the sector's most celebrated names. But investors should be clear about what they are buying. The current product is a temporary implant; the commercial prize depends on a permanent wireless system that its own chief executive says is years from approval. The $250m is therefore best read as runway through a long and uncertain regulatory path, not as payment for revenue. For founders in deep technology, the lesson is that non-traditional investors such as family offices and thematic funds are now willing to finance medical devices on technology-style terms, which brings more money but also more impatience. The signals to watch are the start and early safety data of the fully implantable feasibility study, any progress towards reimbursement, and whether competitors' permanent devices reach patients first.

Sources

• The Next Web: Precision Neuroscience raises $250m at a $1bn valuation, NYT reports
• MedPath: Precision Neuroscience raises $250M Series D to push its brain-surface interface toward permanent implants
• Dealroom: Precision Neuroscience raises $250M for brain-computer interface push
• Wisevoter: Precision Neuroscience raised $250 million in Series D
• BioSpace: Precision Neuroscience receives FDA clearance for high-resolution cortical electrode array
• Pulse 2.0: Precision Neuroscience: $102 million (Series C) raised for advancing AI-based brain implant

Filed under Startups. Written by Invest Times Editorial under our editorial standards. Commentary and analysis for information only, not investment advice.